QualityStocks.net News – NanoViricides Inc. (NNVC.OB) Announces Significant Results in its Anti-HIV Studies

We would like to highlight NanoViricides Inc. (OTCBB: NNVC). The company is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

In 1981, the United States became the first country to identify HIV/AIDS as a distinct condition. Since then, hundreds of thousands of people have become infected, and more than 500,000 have died from the HIV/AIDS virus. It’s a race to arms, as facilities throughout the world conduct studies to combat the virus. NanoViricides Inc. (OTCBB: NNVC) is one such company. Today the company announced that its anti-HIV drug candidates have demonstrated significant therapeutic efficacy in recent preliminary animal studies at a Bio-Safety Level 3 Laboratory facility in Boston, Mass.

The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned figure in preclinical and toxicological studies of innovative therapeutics. In the press release, the company said it anticipates releasing more information on further studies. NanoViricides is now working toward the protocol for a follow up anti-HIV study to be conducted at a major United States government research facility.

“Dr. Menon has indicated to us that the results of the study validate the company’s HivCide-I as a potential treatment for HIV/AIDS,” Eugene Seymour, MD, MPH, CEO of NanoViricides stated in the press release. “Over the next several weeks, we expect to release additional study data.”

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net